$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000119312516670967 Filed on August 04, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$1.759M	$1.680M	$2.083M
YoY Change	-13.99%	-19.35%	-56.62%
Cost Of Revenue	$18.08M	$100.0K	$100.0K
YoY Change	14966.67%	0.0%	11.11%
Gross Profit	-$16.32M	$1.590M	$1.980M
YoY Change	-945.6%	-19.7%	-57.96%
Gross Profit Margin	-927.8%	94.64%	95.06%
Selling, General & Admin	$4.680M	$3.440M	$3.410M
YoY Change	68.95%	0.88%	16.38%
% of Gross Profit		216.35%	172.22%
Research & Development	$6.781M	$8.822M	$2.000M
YoY Change	69.48%	341.1%	-39.92%
% of Gross Profit		554.84%	101.01%
Depreciation & Amortization	$50.00K	$60.00K	$40.00K
YoY Change	25.0%	50.0%	33.33%
% of Gross Profit		3.77%	2.02%
Operating Expenses	$6.781M	$8.822M	$2.000M
YoY Change	69.48%	341.1%	-39.92%
Operating Profit	-$27.79M	-$10.68M	-$7.369M
YoY Change	473.68%	44.93%	377.02%
Interest Expense	$657.0K	$729.0K	$843.0K
YoY Change	-20.56%	-13.52%	-11.24%
% of Operating Profit
Other Income/Expense, Net	-$556.0K	-$610.0K	-$759.0K
YoY Change	-20.46%	-19.63%	116.24%
Pretax Income	-$28.35M	-$11.29M	-$8.130M
YoY Change	411.73%	38.87%	327.89%
Income Tax
% Of Pretax Income
Net Earnings	-$28.35M	-$11.29M	-$8.129M
YoY Change	411.37%	38.89%	328.79%
Net Earnings / Revenue	-1611.43%	-672.02%	-390.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.073M	-$436.8K	-$316.7K
COMMON SHARES
Basic Shares Outstanding	129.5M shares	129.2M shares	128.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$53.40M	$61.70M	$99.20M
YoY Change	-42.89%	-37.8%	77.78%
Cash & Equivalents	$20.67M	$8.643M	$31.49M
Short-Term Investments	$32.70M	$53.00M	$67.70M
Other Short-Term Assets	$1.400M	$1.000M	$800.0K
YoY Change	75.0%	25.0%	100.0%
Inventory
Prepaid Expenses
Receivables	$1.857M	$1.869M	$2.093M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$56.65M	$64.52M	$102.1M
YoY Change	-41.36%	-36.79%	67.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$406.0K	$451.0K	$323.1K
YoY Change	28.7%	39.58%	-26.46%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$3.000K	$3.000K	$61.72K
YoY Change	-94.65%	-95.14%	-21.19%
Total Long-Term Assets	$9.544M	$9.589M	$9.519M
YoY Change	0.4%	0.73%	-26.26%
TOTAL ASSETS
Total Short-Term Assets	$56.65M	$64.52M	$102.1M
Total Long-Term Assets	$9.544M	$9.589M	$9.519M
Total Assets	$66.19M	$74.10M	$111.6M
YoY Change	-37.62%	-33.58%	50.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.056M	$3.875M	$2.385M
YoY Change	96.81%	62.45%	-16.28%
Accrued Expenses	$2.324M	$2.012M	$1.818M
YoY Change	24.02%	10.67%	20.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.104M	$5.429M	$4.846M
YoY Change	5.01%	12.02%	-11.86%
Total Short-Term Liabilities	$12.48M	$11.32M	$9.050M
YoY Change	34.19%	25.04%	-8.82%
LONG-TERM LIABILITIES
Long-Term Debt	$15.80M	$16.54M	$21.79M
YoY Change	-23.56%	-24.1%	-10.59%
Other Long-Term Liabilities	$41.00K	$62.00K	$158.5K
YoY Change	-72.44%	-60.89%	-17.03%
Total Long-Term Liabilities	$15.84M	$16.60M	$21.95M
YoY Change	-23.91%	-24.37%	-10.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.48M	$11.32M	$9.050M
Total Long-Term Liabilities	$15.84M	$16.60M	$21.95M
Total Liabilities	$28.32M	$27.92M	$31.00M
YoY Change	-5.97%	-9.94%	-10.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$887.6M	-$859.3M	-$819.5M
YoY Change	7.58%	4.85%	6.67%
Common Stock	$927.0M	$906.9M	$901.6M
YoY Change	2.71%	0.59%	103265.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$37.87M	$46.19M	$80.58M
YoY Change
Total Liabilities & Shareholders Equity	$66.19M	$74.10M	$111.6M
YoY Change	-37.62%	-33.58%	50.98%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$28.35M	-$11.29M	-$8.129M
YoY Change	411.37%	38.89%	328.79%
Depreciation, Depletion And Amortization	$50.00K	$60.00K	$40.00K
YoY Change	25.0%	50.0%	33.33%
Cash From Operating Activities	-$7.580M	-$10.85M	-$6.790M
YoY Change	69.2%	59.79%	43.55%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$250.0K	$0.00
YoY Change	-75.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$20.24M	$5.370M	$15.73M
YoY Change	622.86%	-65.86%	126.01%
Cash From Investing Activities	$20.22M	$5.130M	$15.73M
YoY Change	632.61%	-67.39%	127.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-620.0K	-320.0K	-920.0K
YoY Change	-44.14%	-65.22%	-1250.0%
NET CHANGE
Cash From Operating Activities	-7.580M	-10.85M	-6.790M
Cash From Investing Activities	20.22M	5.130M	15.73M
Cash From Financing Activities	-620.0K	-320.0K	-920.0K
Net Change In Cash	12.02M	-6.040M	8.020M
YoY Change	-524.73%	-175.31%	256.44%
FREE CASH FLOW
Cash From Operating Activities	-$7.580M	-$10.85M	-$6.790M
Capital Expenditures	-$10.00K	-$250.0K	$0.00
Free Cash Flow	-$7.570M	-$10.60M	-$6.790M
YoY Change	70.5%	56.11%	45.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	129472012	shares
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31485000
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	129462222	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	130685068	shares
CY2016Q2	us-gaap	Assets Assets	74104000
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	66000
CY2016Q2	us-gaap	Assets Current AssetsCurrent	64515000
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7636000
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	905614000
CY2016Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	52971000
CY2016Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	53028000
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8643000
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1869000
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	1307000
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3875000
CY2016Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1237000
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	297000
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	57000
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2012000
CY2016Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16539000
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5429000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7747000
CY2016Q2	us-gaap	Interest Payable Current InterestPayableCurrent	252000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16196884	shares
CY2016Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	53028000
CY2016Q2	us-gaap	Liabilities Liabilities	27917000
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74104000
CY2016Q2	us-gaap	Goodwill Goodwill	8982000
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	62000
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11316000
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	226000
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	836000
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	451000
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	46187000
CY2016Q2	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-859267000
CY2016Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	975000
CY2016Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1524000
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	726000
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128990378	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	130213224	shares
CY2015Q4	us-gaap	Assets Assets	94965000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	44000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	85501000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	903240000
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	49072000
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	49100000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33091000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2106000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	1302000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4217000
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1310000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	123000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1934000
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19558000
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4607000
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	49100000
CY2015Q4	us-gaap	Liabilities Liabilities	30455000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94965000
CY2015Q4	us-gaap	Goodwill Goodwill	8982000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	139000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10758000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	249000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	51000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	278000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	64510000
CY2015Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	153000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-838536000
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1204000
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524000
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	252000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	47000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	31000
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	248000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23738000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6940000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	25432000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	82000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39967000
	us-gaap	Costs And Expenses CostsAndExpenses	42132000
	us-gaap	Revenues Revenues	3741000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1586000
	us-gaap	Net Income Loss NetIncomeLoss	-39977000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	66296000
	us-gaap	Interest Expense InterestExpense	1710000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24854000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	132000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	274000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	16000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38391000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	195000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63137000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-154000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	124000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14545000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-14000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64619000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1677000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019	pure
	us-gaap	Royalty Expense RoyaltyExpense	187000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70	pure
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	24348000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1529000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	75000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	41443000
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	36000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.015	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.71
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10657000
	us-gaap	Share Based Compensation ShareBasedCompensation	1974000
	us-gaap	Royalty Revenue RoyaltyRevenue	3705000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.68	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118199388	shares
	cris	Issuance Of Common Stock To Licensees IssuanceOfCommonStockToLicensees	23968000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	24000
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-24448000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7059000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1890000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	90000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20702000
	us-gaap	Costs And Expenses CostsAndExpenses	22893000
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Revenues Revenues	3406000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1244000
	us-gaap	Net Income Loss NetIncomeLoss	-20731000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	48744000
	us-gaap	Interest Expense InterestExpense	1468000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4164000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-237000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-196000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19487000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	698000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1443000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-346000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	224000
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b><u>Nature of Business</u></b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s most advanced drug candidate is CUDC-907, which is being investigated in clinical studies in patients with diffuse large B-cell lymphoma and solid tumors.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene (Note 4(b)). The collaboration comprises multiple programs, in which Curis has the option to exclusively license compounds once a development candidate is nominated within each respective program. In October 2015, the Company exercised options to license the first two programs under this collaboration. The first licensed program is focused on the development of orally-available small molecule antagonists of programmed death-1 (PD-1) and V-domain Ig suppressor of T-cell activation (VISTA) in the immuno-oncology field. The Company has named CA-170, a programmed death ligand-1 (PD-L1)/VISTA antagonist, as the development candidate from this program. The second licensed program is focused on orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field and the Company has named CA-4948 as the development candidate from this program. In addition, in October 2015, the Company selected a third program for potential further development under the collaboration, the second preclinical program within the immuno-oncology field, which is focused on evaluating small molecule antagonists of PD-1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) pathways, including small molecules that target PD-L1 and TIM-3. The Company has not yet exercised its option to license this third program.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is also party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">®</sup> (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor, in advanced basal cell carcinoma, or BCC. Roche and Genentech are continuing to develop Erivedge in less severe forms of BCC and are conducting studies of Erivedge in other diseases, including in idiopathic pulmonary fibrosis and myelofibrosis.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s proprietary small molecule compounds also include CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, and CUDC-305, a Heat Shock Protein 90, or HSP90, inhibitor.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the FDA and in overseas markets by similar regulatory authorities.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to advance and expand its research and development programs; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à.r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it receives and makes under its current and potential future collaborations. The results of the Company’s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Roche and Genentech’s ongoing clinical trials.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company anticipates that its existing cash, cash equivalents and investments at June 30, 2016 should enable it to maintain current and planned operations into 2017. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, its ability to control expenses and its ability to raise additional funds through equity or debt financings, the success of its collaboration with Genentech, including its receipt of additional contingent cash payments under this collaboration, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of such events is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18841000
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	256000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2141000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.018	pure
	us-gaap	Royalty Expense RoyaltyExpense	184000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	15650000
	us-gaap	Share Based Compensation ShareBasedCompensation	1680000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2194000
	dei	Trading Symbol TradingSymbol	CRIS
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	159000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	44836000
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-180000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
	us-gaap	Royalty Revenue RoyaltyRevenue	3586000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.69	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129142989	shares
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	Plans
	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	-99000
CY2015Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	128000
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3411000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8128000
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	9452000
CY2015Q2	us-gaap	Revenues Revenues	2083000
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-759000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-8128000
CY2015Q2	us-gaap	Interest Expense InterestExpense	843000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7369000
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	84000
CY2015Q2	us-gaap	Royalty Expense RoyaltyExpense	103000
CY2015Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	49000
CY2015Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5938000
CY2015Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1023000
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	2034000
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128351482	shares
CY2016Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	14000
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3443000
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11293000
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	12360000
CY2016Q2	us-gaap	Revenues Revenues	1680000
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-610000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-11290000
CY2016Q2	us-gaap	Interest Expense InterestExpense	729000
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10680000
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	119000
CY2016Q2	us-gaap	Royalty Expense RoyaltyExpense	95000
CY2016Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	-162000
CY2016Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8822000
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	908000
CY2016Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1842000
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129270639	shares

Files In Submission

Name	View Source	Status
0001193125-16-670967-index-headers.html	Edgar Link	pending
0001193125-16-670967-index.html	Edgar Link	pending
0001193125-16-670967.txt	Edgar Link	pending
0001193125-16-670967-xbrl.zip	Edgar Link	pending
cris-20160630.xml	Edgar Link	completed
cris-20160630.xsd	Edgar Link	pending
cris-20160630_cal.xml	Edgar Link	unprocessable
cris-20160630_def.xml	Edgar Link	unprocessable
cris-20160630_lab.xml	Edgar Link	unprocessable
cris-20160630_pre.xml	Edgar Link	unprocessable
d161014d10q.htm	Edgar Link	pending
d161014dex311.htm	Edgar Link	pending
d161014dex312.htm	Edgar Link	pending
d161014dex321.htm	Edgar Link	pending
d161014dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g161014txpg19.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2016 Q3 Form 10-Q Financial Statement

#000119312516670967 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2016 Q3 Form 10-Q Financial Statement

#000119312516670967 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris